Price
CHART BY
Frequently asked questions
What is Sangamo's market capitalization?
The market capitalization of Sangamo is $67.86M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Sangamo?
Sangamo's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -0.383. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Sangamo's stock?
Currently, 1 analysts cover Sangamo's stock, with a consensus target price of $1.00. Analyst ratings provide insights into the stock's expected performance.
What is Sangamo's revenue over the trailing twelve months?
Over the trailing twelve months, Sangamo reported a revenue of $34.56M.
What is the EBITDA for Sangamo?
Sangamo's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$104.32M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Sangamo?
Sangamo has a free cash flow of -$90.46M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Sangamo have, and what sector and industry does it belong to?
Sangamo employs approximately 142 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Sangamo's shares?
The free float of Sangamo is 410.63M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $67.86M
- EPS (TTM)
- -0.383
- Free Float
- 410.63M
- Revenue (TTM)
- $34.56M
- EBITDA (TTM)
- -$104.32M
- Free Cashflow (TTM)
- -$90.46M
Analyst Ratings
The price target is $1.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
- Employees
- 142
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- SGMO
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet